Advanced Cell Dynamics, Inc. (ACD) has reportedly completed a $12-million Series B equity financing round that will support the commercial expansion of the company’s RNAscope®-based products and services. The Hayward, California-based company will also use the proceeds to accelerate RNAscope’s entry into the clinical diagnostics market. ACD apparently offers its products and services globally to scientists in a range of areas, including basic research and companion diagnostics for personalized medicine. According to the company, the technology “is the first automated multiplex in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single-molecule sensitivity.” ACD develops cell- and tissue-based diagnostic tests for personalized medicine. See Advanced Cell Diagnostics, Inc. Press Release, November 1, 2012.